Kinrix and Pramipexole Dihydrochloride

• Generic Name: diphtheria toxoid / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid
• Dosage Forms: injection, suspension
• Other Brand Names: Kinrix, Quadracel

Kinrix is a diphtheria, pertussis acellular, tetanus, and polio vaccine. Diphtheria, pertussis acellular, polio, and tetanus are serious diseases caused by bacteria or virus.

Diphtheria causes a thick coating in the nose, throat, and airway. It can lead to breathing problems, paralysis, heart failure, or death.

Pertussis (whooping cough) causes coughing so severe that it interferes with eating, drinking, or breathing. These spells can last for weeks and can lead to pneumonia, seizures (convulsions), brain damage, and death.

Polio affects the central nervous system and spinal cord. It can cause muscle weakness and paralysis. Polio is a life threatening condition because it can paralyze the muscles that help you breathe.

Tetanus (lockjaw) causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw so the victim cannot open the mouth or swallow. Tetanus leads to death in about 1 out of 10 cases.

Diphtheria, pertussis, and polio are spread from person to person. Tetanus enters the body through a cut or wound.

Kinrix is used to help prevent these diseases in children who are ages 4 through 6 years (before the 7th birthday) who have received prior vaccination with a DTaP and IPV series.

Kinrix works by exposing your child to a small dose of the virus, bacteria or a protein from the bacteria, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

Like any vaccine, Kinrix vaccine may not provide protection from disease in every person.

• Generic Name: pramipexole
• Dosage Forms: n.a.
• Other Brand Names: Mirapex, Mirapex ER

Symptomatic management of idiopathic parkinsonian syndrome.

Used as an adjunct to levodopa for the symptomatic management of parkinsonian syndrome in patients with advanced disease.

Also used as monotherapy for the initial symptomatic management of parkinsonian syndrome. Most clinicians would use levodopa for initial therapy in individuals >70 years of age (less likely than younger individuals to develop levodopa-related motor complications and because of concerns about cognitive dysfunction), in patients with cognitive impairment, and in those with severe disease. A dopamine receptor agonist may be preferred for initial therapy in patients ≤70 years of age.

Symptomatic management of moderate-to-severe primary restless legs syndrome (Ekbom syndrome).